Tickers

1. Composite Trajectory Verdict

Given ARAY's capital-intensive radiation therapy business with significant debt service obligations and a growing services backlog, all three statements — income statement, cash flow statement, and balance sheet — carry roughly equal weight in assessing financial performance.

Composite Trajectory: Deteriorating

The annual comparison shows broad-based deterioration across all three financial statements. Revenue fell 12% year-over-year (10-K 2026-06-30, Consolidated Statements of Operations), gross margin compressed 440 basis points to 27.7% (10-K 2026-06-30, MD&A), and the company swung from a $7.8 million operating profit to a $26.4 million operating loss (10-K 2026-06-30, Consolidated Statements of Operations). Operating cash flow turned negative at -$7.0 million versus +$2.9 million a year earlier (10-K 2026-06-30, Consolidated Statements of Cash Flows). Total stockholders' equity dropped 49% to $41.7 million while net debt rose 8% to $147.9 million (10-K 2026-06-30, Consolidated Balance Sheets). No improving trend offsets these declines.

2. Red Flags

• Net loss widened from $1.6 million to $49.2 million (10-K 2026-06-30, Consolidated Statements of Operations)
• Operating cash flow reversed from +$2.9 million to -$7.0 million (10-K 2026-06-30, Consolidated Statements of Cash Flows)
• Gross margin fell from 32.1% to 27.7% despite services revenue growing 4% (10-K 2026-06-30, MD&A)
• Total interest expense surged 154% to $32.9 million, driven by PIK interest and warrant amortization (10-K 2026-06-30, MD&A)
• Stockholders' equity declined 49% to $41.7 million as accumulated deficit grew to $568.5 million (10-K 2026-06-30, Consolidated Balance Sheets)
• Net debt increased to $147.9 million from $136.5 million while cash fell to $40.6 million from $57.4 million (10-K 2026-06-30, Consolidated Balance Sheets)
• Order backlog contracted 27% to $312.5 million from $427.0 million (10-K 2026-06-30, MD&A)
• Book-to-bill ratio declined from 1.2 to 1.1 (10-K 2026-06-30, MD&A)
• Company was not in compliance with minimum liquidity covenant as of June 30, 2026 (10-K 2026-06-30, Note 7)
• Nasdaq bid price deficiency notice received February 2026, extended compliance period to February 2027 (10-K 2026-06-30, Note 1)

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Deteriorating

Overall Assessment: Net revenue declined 12% to $401.9 million driven by a 27% drop in product revenue to $172.7 million, partially offset by 4% services growth to $229.2 million (10-K 2026-06-30, Consolidated Statements of Operations). Gross profit fell 24% to $111.5 million with margin compression from 32.1% to 27.7% attributed to non-IEEPA tariff expense and unfavorable product/region mix (10-K 2026-06-30, MD&A). Total operating expenses decreased only 1% to $137.9 million despite a $16.2 million restructuring charge, while R&D, S&M, and G&A each fell 21%, 11%, and 5% respectively (10-K 2026-06-30, Consolidated Statements of Operations). The company swung from $7.8 million operating income to a $26.4 million operating loss. Interest expense more than doubled to $32.9 million due to new financing arrangements (10-K 2026-06-30, MD&A). Net loss per share widened from -$0.02 to -$0.40 on a higher share count (10-K 2026-06-30, Consolidated Statements of Operations).

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Deteriorating

Overall Assessment: Net cash used in operating activities was $7.0 million versus $2.9 million provided in the prior year, driven by a $49.2 million net loss partially offset by $30.4 million in non-cash items including $9.7 million PIK interest and $8.1 million debt discount amortization (10-K 2026-06-30, Consolidated Statements of Cash Flows). Working capital changes provided $11.9 million, led by an $11.5 million accounts receivable decrease and $7.0 million deferred revenue increase, partly offset by a $12.5 million inventory build (10-K 2026-06-30, Consolidated Statements of Cash Flows). Investing cash outflows increased to $12.3 million from $8.5 million on higher capitalized software ($6.4 million) and property/equipment purchases ($5.9 million) (10-K 2026-06-30, Consolidated Statements of Cash Flows). Financing activities provided $7.0 million versus $4.3 million used, primarily from $19.0 million revolver borrowings, $18.3 million delayed draw facility, and $6.6 million IEEPA financing proceeds, partly offset by $18.0 million convertible note payoff and $14.0 million revolver repayments (10-K 2026-06-30, Consolidated Statements of Cash Flows). Total cash and restricted cash fell to $48.8 million from $62.1 million (10-K 2026-06-30, Consolidated Statements of Cash Flows).

5. Balance Sheet Assessment

Balance Sheet Trajectory: Deteriorating

Overall Assessment: Total assets declined 6% to $443.7 million from $470.2 million (10-K 2026-06-30, Consolidated Balance Sheets). Cash and cash equivalents dropped 29% to $40.6 million (10-K 2026-06-30, Consolidated Balance Sheets). Accounts receivable fell 19% to $67.4 million while inventories rose 4% to $147.1 million (10-K 2026-06-30, Consolidated Balance Sheets). Total liabilities increased 3% to $402.0 million, with long-term debt net rising 18% to $146.4 million and short-term debt falling to $1.5 million from $12.7 million (10-K 2026-06-30, Consolidated Balance Sheets). Warrant liability decreased to $2.4 million from $8.5 million on fair value gains (10-K 2026-06-30, Consolidated Balance Sheets). Stockholders' equity fell 49% to $41.7 million as accumulated deficit grew to $568.5 million from $519.3 million (10-K 2026-06-30, Consolidated Balance Sheets). The debt-to-equity ratio worsened materially, and the company was not in compliance with its minimum liquidity covenant at year-end (10-K 2026-06-30, Note 7).

6. Data Gaps

• Quarterly year-over-year trends for revenue, margins, cash flow, and balance sheet metrics (10-Qs provided do not include comparable prior-year quarters)
• Free cash flow (operating cash flow minus capital expenditures) not explicitly reported
• Segment-level profitability by product platform (CyberKnife vs. helical) or geography
• Detailed breakdown of "non-IEEPA tariff expense" impact on cost of revenue
• Covenant compliance metrics (leverage ratio, fixed charge coverage ratio) beyond liquidity covenant
• Expected timing and amount of remaining $40 million Series A preferred stock closing conditions
• Full year FY2027 guidance for revenue, gross margin, and cash flow beyond qualitative statements